These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 32961897)

  • 1. Induction of the Antiviral Immune Response and Its Circumvention by Coronaviruses.
    Liu P; Hong Y; Yang B; Shrestha P; Sajjad N; Chen JL
    Viruses; 2020 Sep; 12(9):. PubMed ID: 32961897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
    Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
    Front Immunol; 2020; 11():1949. PubMed ID: 32849654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A molecular arms race between host innate antiviral response and emerging human coronaviruses.
    Wong LY; Lui PY; Jin DY
    Virol Sin; 2016 Feb; 31(1):12-23. PubMed ID: 26786772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surviving COVID-19: A disease tolerance perspective.
    Ayres JS
    Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
    [No Abstract]   [Full Text] [Related]  

  • 5. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
    Park A; Iwasaki A
    Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
    Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
    Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2-A Tough Opponent for the Immune System.
    Nasab MG; Saghazadeh A; Rezaei N
    Arch Med Res; 2020 Aug; 51(6):589-592. PubMed ID: 32532524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
    Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.
    Mellors J; Tipton T; Longet S; Carroll M
    Front Immunol; 2020; 11():1450. PubMed ID: 32733480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses.
    Fung SY; Yuen KS; Ye ZW; Chan CP; Jin DY
    Emerg Microbes Infect; 2020; 9(1):558-570. PubMed ID: 32172672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
    Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
    Front Immunol; 2020; 11():1979. PubMed ID: 32973803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.
    Bouayad A
    Rev Med Virol; 2020 Nov; 30(6):1-9. PubMed ID: 32734714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development.
    Zhao X; Chen D; Li X; Griffith L; Chang J; An P; Guo JT
    J Mol Biol; 2022 Mar; 434(6):167438. PubMed ID: 34990653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences and similarities between innate immune evasion strategies of human coronaviruses.
    Hoenigsperger H; Sivarajan R; Sparrer KM
    Curr Opin Microbiol; 2024 Jun; 79():102466. PubMed ID: 38555743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).
    Chang FY; Chen HC; Chen PJ; Ho MS; Hsieh SL; Lin JC; Liu FT; Sytwu HK
    J Biomed Sci; 2020 Jun; 27(1):72. PubMed ID: 32498686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs.
    Bartoszewski R; Dabrowski M; Jakiela B; Matalon S; Harrod KS; Sanak M; Collawn JF
    Am J Physiol Lung Cell Mol Physiol; 2020 Sep; 319(3):L444-L455. PubMed ID: 32755307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interplay between SARS-CoV-2 and the type I interferon response.
    Sa Ribero M; Jouvenet N; Dreux M; Nisole S
    PLoS Pathog; 2020 Jul; 16(7):e1008737. PubMed ID: 32726355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.